Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2025)

Vivos Therapeutics has reported Operating Expenses over the past 6 years, most recently at $9.4 million for Q4 2025.

  • Quarterly Operating Expenses rose 91.11% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.4 million through Dec 2025, up 50.78% year-over-year, with the annual reading at $30.4 million for FY2025, 50.75% up from the prior year.
  • Operating Expenses was $9.4 million for Q4 2025 at Vivos Therapeutics, up from $8.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $10.5 million in Q4 2021 and troughed at $4.6 million in Q2 2024.
  • The 5-year median for Operating Expenses is $7.2 million (2023), against an average of $7.2 million.
  • Year-over-year, Operating Expenses soared 97.43% in 2021 and then crashed 31.84% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $10.5 million in 2021, then fell by 19.69% to $8.4 million in 2022, then dropped by 26.34% to $6.2 million in 2023, then decreased by 21.2% to $4.9 million in 2024, then soared by 91.11% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Expenses are $9.4 million (Q4 2025), $8.7 million (Q3 2025), and $7.0 million (Q2 2025).